Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of September 30, 2023, is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Investor Conferences
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Arvinas price target lowered to $52 from $62 at BofA
- Arvinas price target lowered to $36 from $72 at Citi